home.aspx
 
EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...

Aesica Pharmaceuticals Ltd

SHARESHARESHARE
Aesica is a leading pharmaceutical contract development and manufacturing organisation (CDMO) for both APIs and finished dose forms. Our full service, end-to-end pharmaceutical development and manufacturing solution comprises capabilities in formulation development for API and finished dose, manufacturing at all scales and packaging services.
SHARESHARESHARE

RELATED NEWS


IBM Watson Health and Pfizer Inc announced a collaboration that will utilize IBM Watson for Drug Discovery to help accelerate Pfizer's research in immuno-oncology, an approach to cancer treatment that uses the body's immune system to help fight cancer....

READ MORE

Merck & Company announced that its investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age. The Phase II study, called V114-008, met its primary endpoint, showing noninferiority for the 13 serotypes seen in both vaccines. V114 also caused an immune response in infants for two additional disease-causing serotypes, 22F and 33F, which aren’t in PCV13.


READ MORE

Merck KGaA and Pfizer’s late entrant to the checkpoint inhibitor category has failed a phase III trial in ovarian cancer, denting their hopes of building momentum for the product. The JAVELIN Ovarian 200 study was testing Bavencio (avelumab) alone or in combination with chemotherapy (pegylated doxorubicin) in patients with resistant or refractory ovarian cancer, but who showed that the PD-L1 inhibitor wasn’t able to improve either progression-free survival or overall survival. It&rsq...

READ MORE

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiation treatment....

READ MORE

Biotech and pharmaceutical stocks rose after the November election, reflecting investor optimism that a Trump presidency would mean less focus on drug prices....
CHICAGOTRIBUNE.COM
READ MORE

US-based Vertex Pharmaceuticals has signed an agreement to acquire CTP-656, an investigational cystic fibrosis transmembrane conductance regulator (CFTR) potentiator from Concert Pharmaceuticals for up to $250m....

READ MORE

EVENTS

THE 2021 CLINICAL DISCLOSURE VIRTUAL
THE 2021 CLINICAL DISCLOSURE VIRTUAL
May 11-12, 2021
Sophisticated and fully interactive conference experience, leverage best practices, networking and on-demand sessions will be available in one place, at the touch of a button.

Discover how Clinical Data Disclosure, Transparency & Plain Language Summaries Virtual Platform will elev...

Pharma Manufacturing Automation 2021
PHARMA MANUFACTURING AUTOMATION 2021
May 18-19, 2021
As the use of the robotics in the pharmaceutical manufacturing industry increases rapidly, it’s important to consider the benefits of the latest technologies for manufacturers, researchers and scientists. The advantages include greater speed and accuracy, more flexibility and more reliability ...